Jerome Winegarden: ASH Continues to Show Exceptional Leadership by Advocating for Patients With Blood Diseases
Jerome Winegarden, Attending Physician and Hematology Oncology Fellowship Program Director at Trinity Health, reposted from American Society of Hematology on LinkedIn:
”ASH continues to show exceptional leadership by advocating for patients with blood diseases.
Standing up for science is not just a great tag line!
It really means something to the millions of people who suffer from blood cancers and blood related diseases.
I’m so proud to be an ASH member.”
Quoting American Society of Hematology‘s post:
”Boldly Standing Up for Science.
2025 brought unprecedented political threats to scientific research, federal funding, and access to care, but hematology thrived.
Through the hashtag Fight 4 Hematology campaign, the Society stepped up to expand research funding and training opportunities, lead impassioned advocacy efforts, and amplify the voices of clinicians, researchers, and patients.
ASH is proud to serve hematologists who are dedicated to conquering blood diseases and improving the lives of patients around the world.
Thank you for being an ASH member and helping to make 2025 such a success!
View the 2025 ASH Annual Report.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids